SH PHARMA's Pregabalin Capsules Secure Pharmaceutical Registration in the Philippines

Stock News02-27

SH PHARMA (02607) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has obtained a pharmaceutical registration certificate from the Philippines' Food and Drug Administration for its Pregabalin Capsules, approving the product for market launch. Pregabalin Capsules are primarily used to treat postherpetic neuralgia, diabetic peripheral neuropathic pain, fibromyalgia, neuropathic pain associated with spinal cord injury, and as an adjunctive therapy for epilepsy. The approval covers three specifications (50mg, 75mg, and 150mg) of Pregabalin Capsules. This milestone signifies the company's eligibility to market the product in the Philippines, which is expected to positively impact its overseas expansion efforts and provide valuable experience.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186811922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186811922","market":"sg","top_or_hot":-1,"title":"SH PHARMA's Pregabalin Capsules Secure Pharmaceutical Registration in the Philippines","media":"Stock News","content":"<p>SH PHARMA (02607) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has obtained a pharmaceutical registration certificate from the Philippines' Food and Drug Administration for its Pregabalin Capsules, approving the product for market launch. Pregabalin Capsules are primarily used to treat postherpetic neuralgia, diabetic peripheral neuropathic pain, fibromyalgia, neuropathic pain associated with spinal cord injury, and as an adjunctive therapy for epilepsy. The approval covers three specifications (50mg, 75mg, and 150mg) of Pregabalin Capsules. This milestone signifies the company's eligibility to market the product in the Philippines, which is expected to positively impact its overseas expansion efforts and provide valuable experience.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SH PHARMA's Pregabalin Capsules Secure Pharmaceutical Registration in the Philippines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSH PHARMA's Pregabalin Capsules Secure Pharmaceutical Registration in the Philippines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-27 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SH PHARMA (02607) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has obtained a pharmaceutical registration certificate from the Philippines' Food and Drug Administration for its Pregabalin Capsules, approving the product for market launch. Pregabalin Capsules are primarily used to treat postherpetic neuralgia, diabetic peripheral neuropathic pain, fibromyalgia, neuropathic pain associated with spinal cord injury, and as an adjunctive therapy for epilepsy. The approval covers three specifications (50mg, 75mg, and 150mg) of Pregabalin Capsules. This milestone signifies the company's eligibility to market the product in the Philippines, which is expected to positively impact its overseas expansion efforts and provide valuable experience.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1186811922","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186811922","pubTimestamp":1772181887,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SH PHARMA (02607) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has obtained a pharmaceutical registration certificate from the Philippines' Food and Drug Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0188":"融资融券","BK0012":"证金概念","BK0175":"白马股","02607":"上海医药","BK0196":"行业龙头","BK0183":"MSCI概念","BK0184":"上海国资改革","BK0187":"一线龙头","BK0097":"医药电商","BK0099":"上海本地重组","BK1197":"保健护理产品经销商","BK0020":"浦东新区","BK0209":"零售","BK0028":"国家队"},"translate_title":"SH PHARMA的普瑞巴林胶囊在菲律宾获得药品注册","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"SH PHARMA (02607) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has obtained a pharmaceutical registration certificate from the Philippines' Food and Drug Administration for its Pregabalin Capsules, approving the product for market launch. Pregabalin Capsules are primarily used to treat postherpetic neuralgia, diabetic peripheral neuropathic pain, fibromyalgia, neuropathic pain associated with spinal cord injury, and as an adjunctive therapy for epilepsy. The approval covers three specifications (50mg, 75mg, and 150mg) of Pregabalin Capsules. This milestone signifies the company's eligibility to market the product in the Philippines, which is expected to positively impact its overseas expansion efforts and provide valuable experience.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186811922","isCrawlerRequest":true}